-
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
-
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
-
Zelluna promotes Emilie Gauthy to Chief Technology Officer
-
Zelluna promotes Emilie Gauthy to Chief Technology Officer
-
Zelluna ASA: Approval and publication of prospectus
-
Zelluna ASA: Approval and publication of prospectus
-
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
-
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
-
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World’s First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
-
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
